Author

A Sanchez

Institutions: University of Iowa, University of Iowa Hospitals and Clinics

Observed institutions: University of Iowa, University of Iowa Hospitals and Clinics

OpenAlex ID: A5113493283

Exploring the role of ileal bile acid transporter inhibitors, like volixibat, in the regulation of IL-31 and serum bile acids in patients with primary biliary cholangitis: Preliminary results from the VANTAGE trial

2026 · J Trebicka, A Bonder, et al. · Zeitschrift für Gastroenterologie

Volixibat leads to improvements in fatigue and sleep for adults with primary biliary cholangitis: Data from VANTAGE

2026 · J Trebicka, K V Kowdley, et al. · Zeitschrift für Gastroenterologie

Volixibat zur Behandlung des cholestatischen Pruritus bei primär biliärer Cholangitis: Zwischenergebnisse der adaptiven, randomisierten, placebokontrollierten Phase-IIb-Studie (VANTAGE)

2025 · J Trebicka, K V Kowdley, et al. · Zeitschrift für Gastroenterologie

Works count: 3

Citation count:

H-index:

I10-index: